Author(s)

HongJian Wei¹, Yan Liu¹, Ming Xu^2*

Affiliation(s)

¹The Third People’s Hospital of Hunan Province, Yueyang 414000, Hunan, China.

²Hunan Provincial People's Hospital/The first affiliated hospital of Hunan Normal University, Changsha 410000, Hunan, China.

Corresponding Author

Ming Xu

ABSTRACT

Objective: To study the effects of spleen-strengthening meal replacement powder on ascites in liver cirrhosis. Methods: Sixty patients with liver cirrhosis and ascites, who received treatment at our hospital, were selected as the study subjects. The selected patients were randomly divided into two groups, Group I and Group II (30 cases per group). After discharge, Group I continued with a low-salt diet and diuretics as standard treatment and was given a meal replacement powder without spleen-strengthening effects as breakfast. Group II continued with diuretics as standard treatment and was given a spleen-strengthening meal replacement powder as breakfast, with the rest of the diet following a low-salt diet standard. Both groups were continuously observed and treated for six months. Ascites indicators before and after treatment in both groups were measured. Results: Group II showed higher treatment efficacy and quality of life, with P<0.05. Conclusion: Spleen-strengthening meal replacement powder has a certain effect on the treatment and relief of ascites in liver cirrhosis and is worth promoting in clinical practice.

KEYWORDS

Spleen-strengthening meal replacement powder; Ascites in liver cirrhosis

CITE THIS PAPER

HongJian Wei, Yan Liu, Ming Xu. Study on the effects of spleen-strengthening meal replacement powder on ascites in liver cirrhosis. Journal of Pharmaceutical and Medical Research. 2024, 6(3): 12-15. DOI: 10.61784/jpmr3009.

REFERENCES

[1] Incicco S ,Angeli P ,Piano S . Infectious Complications of Portal Hypertension. Clinics in Liver Disease, 2024, 28 (3): 525-539.

[2] Long C ,Ma Q ,Huang L et al. A near-infrared fluorescent probe for differentiating cancer cells from normal cells and early diagnosis of liver cirrhosis. Analytica Chimica Acta, 2024, 1316 342802-.

[3] Kanhar S ,Swain K S, Dash C U et al. Antioxidants of commercial interest from Homalium tomentosum attenuates hepatocellular necrosis: Insights from experimental and computational studies. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2024, 322 124741-124741.

[4] Elsabaawy M M, Assem M, Badran H et al. Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis. European journal of gastroenterology & hepatology, 2024, 36 (8): 1022-1028.

[5] Donato F ,Pigozzi G M ,Colarieti G , et al. Why are rare diseases underdiagnosed? A clinical management study on detection of primary biliary cholangitis in primary care. [J]. Annali di igiene : medicina preventiva e di comunita, 2024, 36 (5): 614-618.

[6] Xu X ,Ding H ,Jia J et al. Chinese guidelines on the management of ascites in cirrhosis : Chinese Society of Hepatology, Chinese Medical Association. Hepatology international, 2024,

[7] Song S ,Wang Z ,Liu K et al. Perioperative impact of liver cirrhosis on robotic liver resection for hepatocellular carcinoma: a retrospective cohort study. Surgical endoscopy, 2024,

[8] Deyu H, Jiejuan L ,Quanyu C et al. New advances of NG2-expressing cell subset in marrow mesenchymal stem cells as novel therapeutic tools for liver fibrosis/cirrhosis. Stem Cell Research & Therapy, 2024, 15 (1): 199.

[9] Yuxia C, Meijuan W, Meng C et al. A non-invasive diagnostic nomogram for CHB-related early cirrhosis: a prospective study. Scientific Reports, 2024, 14 (1): 15343.

[10] Miwa T, Hanai T, Hirata S et al. Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study. Clinical nutrition ESPEN, 2024, 63 267-273.

[11] Gantzel H R, M?ller E E ,Aagaard K N et al. Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites. Hepatology communications, 2024, 8 (7):

[12] Mohammedsaeed W, Alghamdi J Z. Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia. Saudi medical journal, 2024, 45 (7): 675-684.